Please assess the completion status of the following clinical trial:

Trial Title: Stop Atherosclerosis in Native Diabetics Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. American Indian men and women 40 years of age or older~2. Type 2 DM (according to 1997 ADA criteria and/or previously diagnosed by former ADA or WHO criteria): fasting plasma glucose \>= 7.0 mmol/L (126 mg/dL) or 2-hour glucose \>= 11.0 mmol/L (\>200 mg/dL) after a 75-gram oral glucose tolerance test.~3. LDL cholesterol \>= 100 mg/dL. within the previous 12 months.~4. Systolic BP \>= 130 mm Hg. within the previous 12 months.~Exclusion Criteria:~1. New York Heart Association Stage III- IV congestive heart failure.~2. SBP \>180 mmHg (2% of population) or patients with known causes of hypertension.~3. History of angioedema.~4. Any medical condition that study physicians believe would interfere with study participation or evaluation of results.~5. Mental incapacity and/or cognitive impairment on the part of the patient that would preclude adequate understanding of, or cooperation with, the study protocol.~6. Serum hepatic transaminase levels 2X the upper limit of normal.~7. Participation in any clinical trial of any investigational medication within 3 months prior to this trial.~8. Renal insufficiency as indicated by serum creatinine \>2.0 for women and \>2.4 for men.~9. Diagnosis of primary hyperlipidemia in medical record.~10. Secondary hypercholesterolemia due to hypothyroidism or nephrotic syndrome. Patients on stable doses of thyroid replacement therapy will be eligible.~11. Presence of malignancy or history of any cancer except skin cancer within the past 5 years.~12. Pregnancy or lactation. Premenopausal women will be requested to use birth control methods throughout the study and provided educational materials about the risks of using the study medications during pregnancy.~13. Unable to obtain quantifiable carotid measure during screening examination.~14. Concomitant long term use of cyclosporins (Sandimmune), macrolide antibiotics (erythromycin -many generic and brand name forms, clarithromycin, Biaxin, and Zithromax), azole antifungals (itraconazole-Sporanox, ritonavir, Norvir, and nelfinavir (Viracept).~15. Orthostatic hypotension as defined by the following:~    1. The individual has a measured fall of \>20 mmHg in systolic BP upon standing associated with symptoms lasting more than one minute (or severe symptoms that would not allow further lowering of BP)~   2. The standing systolic blood pressure is less than 90 mm.~16. Triglyceride level \>350 mg/dl.~17. Severe aortic stenosis with valve area \<=1.0 square cm.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SANDS Control Group (Type: NO_INTERVENTION): Standard Treatment for blood pressure and cholesterol
- SANDS Intervention Group (Type: ACTIVE_COMPARATOR): FDA approved drugs to treat blood pressure and cholesterol

Based on this trial design, predict the completion outcome and termination type (if applicable).